A prospective, multicenter, randomised, double-blind, placebo-controlled, 2-parallel groups, Phase 3 study to compare the efficacy and the safety of masitinib at 6 mg/kg/day versus placebo in the treatment of patients with Severe Persistent Asthma treated with oral corticosteroids

Trial Profile

A prospective, multicenter, randomised, double-blind, placebo-controlled, 2-parallel groups, Phase 3 study to compare the efficacy and the safety of masitinib at 6 mg/kg/day versus placebo in the treatment of patients with Severe Persistent Asthma treated with oral corticosteroids

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 31 Aug 2017

At a glance

  • Drugs Masitinib (Primary)
  • Indications Asthma
  • Focus Registrational; Therapeutic Use
  • Sponsors AB Science
  • Most Recent Events

    • 31 Aug 2017 According to an AB Science media release, the Independent Data Monitoring Committee (IDMC) has indicated that the study can continue on the basis of safety data and did not request implementation of the protocol resampling option. The company had communicated its decision to continue the study until completion even in the event of successful interim analysis tot he IDMC prior to the analysis.
    • 31 Aug 2017 According to an AB Science media release, final results from this trial are expected at the end of 2017.
    • 31 Aug 2017 According to an AB Science media release, status changed from recruiting to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top